26,645 Intuitive Surgical, Inc. $ISRG Shares Sold by SteelPeak Wealth LLC

SteelPeak Wealth LLC lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 68.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,535 shares of the medical equipment provider’s stock after selling 26,645 shares during the quarter. SteelPeak Wealth LLC’s holdings in Intuitive Surgical were worth $5,097,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in shares of Intuitive Surgical by 3.3% in the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after acquiring an additional 116,292 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Intuitive Surgical during the second quarter worth approximately $1,335,753,000. Amundi raised its position in shares of Intuitive Surgical by 8.6% in the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after buying an additional 193,096 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in shares of Intuitive Surgical by 95.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after purchasing an additional 1,027,475 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Intuitive Surgical by 13.8% during the first quarter. Assenagon Asset Management S.A. now owns 1,745,008 shares of the medical equipment provider’s stock valued at $804,431,000 after buying an additional 211,237 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Gary Guthart sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total value of $4,000,000.00. Following the completion of the transaction, the director directly owned 1,245,679 shares in the company, valued at approximately $498,271,600. This represents a 0.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $379.00, for a total transaction of $151,600.00. Following the transaction, the executive vice president owned 5,320 shares of the company’s stock, valued at approximately $2,016,280. This represents a 6.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 12,370 shares of company stock worth $4,891,989. 0.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ISRG has been the topic of several recent research reports. Robert W. Baird reduced their price target on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating on the stock in a research report on Friday, July 17th. BNP Paribas Exane raised shares of Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. Oppenheimer upgraded Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price objective for the company in a research note on Wednesday, August 12th. Evercore set a $430.00 price target on shares of Intuitive Surgical in a research note on Monday, July 6th. Finally, Citigroup decreased their target price on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $498.83.

Intuitive Surgical Stock Down 0.3%

ISRG opened at $426.70 on Friday. The firm has a market capitalization of $150.74 billion, a P/E ratio of 48.88, a PEG ratio of 3.22 and a beta of 1.46. The stock has a fifty day moving average of $391.43 and a 200-day moving average of $409.74. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, analysts expect that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts at Erste Group Bank raised their earnings estimates for ISRG, suggesting improved expectations for the company’s upcoming results and longer-term profitability. Erste Group Bank Analysts Boost Earnings Estimates for ISRG
• Positive Sentiment: Recent results have shown double-digit growth in robotic-surgery procedures, revenue and Intuitive Surgical’s installed base of systems. That underlying operating momentum remains a key support for the investment case despite the stock’s broader underperformance this year. Intuitive Surgical Valuation and Growth
• Positive Sentiment: The shares increased in the prior session and outperformed the broader market that day, reflecting some investor support ahead of the earnings release. ISRG Beats Stock Market Upswing
• Neutral Sentiment: Investors are focused on third-quarter procedure growth, da Vinci system demand, revenue, margins and other operating metrics—not just earnings per share and revenue—to determine whether recent momentum is sustainable. ISRG Ahead of Q3 Earnings
• Negative Sentiment: Expectations are tempered by slowing U.S. procedure growth and headwinds in China. These issues could pressure system placements and margins, increasing the risk of an earnings-related market reaction. ISRG Q3 Earnings Preview
• Negative Sentiment: Despite double-digit growth, shares have declined substantially during 2026 and trade at a premium valuation. Investors are questioning whether a valuation around 33 times expected earnings adequately reflects the company’s growth prospects, particularly if procedure growth slows. ISRG Valuation Analysis

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.